Literature DB >> 3681290

Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors?

L Nilsson1, A Adem, J Hardy, B Winblad, A Nordberg.   

Abstract

In the presence of 9-amino-1,2,3,4-tetrahydroacridine (THA) 10(-4) M or physostigmine 10(-4) M, the in vitro 3H-Acetylcholine (3H-ACh) release from control cortical slices was significantly reduced. In contrast, THA 10(-4) M and physostigmine 10(-4) M significantly increased the release of 3H-ACh in AD/SDAT brain tissue. This facilitating effect on 3H-ACh release was partially blocked (50%) in the presence of the nicotinic antagonist d-tubocurarine 10(-6) M indicating a possible interaction via nicotinic receptors. The muscarinic antagonist atropine 10(-5) M significantly increased the 3H-ACh release both in control and AD/SDAT brains, thus indicating preservation of muscarinic autoreceptors in the AD/SDAT cortical tissue. In receptor competition studies with 3H-nicotine, 3H-ACh and 3H-quinuclidinyl benzilate (3H-QNB) as receptor ligands, THA interfered with both nicotinic and muscarinic receptor ligand binding, while physostigmine had much less effect.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3681290     DOI: 10.1007/bf01253610

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  22 in total

1.  Transmitter deficits in Alzheimer's disease.

Authors:  J Hardy; R Adolfsson; I Alafuzoff; G Bucht; J Marcusson; P Nyberg; E Perdahl; P Wester; B Winblad
Journal:  Neurochem Int       Date:  1985       Impact factor: 3.921

Review 2.  Cholinergic approaches to the treatment of Alzheimer's disease.

Authors:  E Hollander; R C Mohs; K L Davis
Journal:  Br Med Bull       Date:  1986-01       Impact factor: 4.291

3.  Anatoxin-a a potent ligand for nicotinic cholinergic receptors in rat brain.

Authors:  X Zhang; P Stjernlöf; A Adem; A Nordberg
Journal:  Eur J Pharmacol       Date:  1987-03-31       Impact factor: 4.432

Review 4.  The cholinergic hypothesis--ten years on.

Authors:  E K Perry
Journal:  Br Med Bull       Date:  1986-01       Impact factor: 4.291

5.  Cortical muscarinic receptor subtypes and Alzheimer's disease.

Authors:  M P Caulfield; D W Straughan; A J Cross; T Crow; N J Birdsall
Journal:  Lancet       Date:  1982-12-04       Impact factor: 79.321

6.  Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation.

Authors:  D C Mash; D D Flynn; L T Potter
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

7.  The effect of nicotine and cytisine on 3H-acetylcholine release from cortical slices of guinea-pig brain.

Authors:  L Beani; C Bianchi; L Nilsson; A Nordberg; L Romanelli; L Sivilotti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

8.  Presynaptic nicotine receptors mediating a positive feed-back on transmitter release from the rat phrenic nerve.

Authors:  I Wessler; M Halank; J Rasbach; H Kilbinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-12       Impact factor: 3.000

9.  Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains.

Authors:  A Nordberg; B Winblad
Journal:  Neurosci Lett       Date:  1986-12-03       Impact factor: 3.046

10.  Muscarinic receptor subtypes in hippocampus in Alzheimer's disease and mixed dementia type.

Authors:  A Nordberg; I Alafuzoff; B Winblad
Journal:  Neurosci Lett       Date:  1986-09-25       Impact factor: 3.046

View more
  10 in total

Review 1.  Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

Authors:  A Nordberg; A L Svensson
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 2.  Activating the damaged basal forebrain cholinergic system: tonic stimulation versus signal amplification.

Authors:  M Sarter; J P Bruno; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 3.  The neuronal nicotinic acetylcholine receptor in some hereditary epilepsies.

Authors:  F J Barrantes; E Aztiria; M B Rauschemberger; A Vasconsuelo
Journal:  Neurochem Res       Date:  2000-05       Impact factor: 3.996

4.  Effect of nicotine and tacrine on acetylcholine release from rat cerebral cortical slices.

Authors:  R E Loiacono; F J Mitchelson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-07       Impact factor: 3.000

5.  The mechanism of tetrahydroaminoacridine-evoked release of endogenous 5-hydroxytryptamine and dopamine from rat brain tissue prisms.

Authors:  T N Robinson; R J De Souza; A J Cross; A R Green
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

Review 6.  The cholinergic hypothesis of Alzheimer's disease: a review of progress.

Authors:  P T Francis; A M Palmer; M Snape; G K Wilcock
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-02       Impact factor: 10.154

7.  Mecamylamine reverses physostigmine-induced attenuation of scopolamine-induced hyperactivity.

Authors:  M F O'Neill; A G Fernández; R W Gristwood; J M Palacios
Journal:  J Neural Transm Gen Sect       Date:  1994

8.  Behavioral effects after intrathecal administration of cholinergic receptor agonists in the rat.

Authors:  P G Gillberg; P Hartvig; T Gordh; A Sottile; I Jansson; T Archer; C Post
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

9.  Blockade of nicotinic responses by physostigmine, tacrine and other cholinesterase inhibitors in rat striatum.

Authors:  P B Clarke; M Reuben; H el-Bizri
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

Review 10.  Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease.

Authors:  A J Wagstaff; D McTavish
Journal:  Drugs Aging       Date:  1994-06       Impact factor: 3.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.